Analyst Price Targets — SLDB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 4, 2025 11:41 am | Gil Blum | Needham | $16.00 | $5.19 | TheFly | Solid Biosciences initiated with a Buy at Needham |
| November 4, 2025 10:08 am | — | Barclays | $9.00 | $5.20 | TheFly | Solid Biosciences price target lowered to $9 from $10 at Barclays |
| July 21, 2025 11:52 am | Charles Duncan | Cantor Fitzgerald | $16.00 | $6.76 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB) |
| June 24, 2024 6:09 am | Joseph Schwartz | Leerink Partners | $12.00 | $6.62 | StreetInsider | Leerink Partners Upgrades Solid Biosciences (SLDB) to Outperform |
| May 31, 2024 5:07 am | Biren Amin | Piper Sandler | $20.00 | $7.64 | TheFly | Solid Biosciences transferred with Overweight rating at Piper Sandler |
| May 16, 2024 5:10 am | Gena Wang | Barclays | $18.00 | $9.69 | TheFly | Solid Biosciences price target lowered to $18 from $21 at Barclays |
| March 13, 2024 4:07 pm | Christopher Raymond | Raymond James | $20.00 | $12.23 | StreetInsider | Piper Sandler Upgrades Solid Biosciences (SLDB) to Overweight, 'Still See Significant Upside Potential Despite Recent Move' |
Latest News for SLDB
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Bo Cumbo, President and CEO, will participate in a virtual fireside chat on…
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The stock traded as high as $7.61 and last traded at $7.63. 335,353 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,345,952
Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average 12-month
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 -
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 549,182 shares of the company's stock after selling 174,818 shares during
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLDB.
U.S. House Trading
No House trades found for SLDB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.